The Ministry of Health, the Ministry of Finance and the Federal Antimonopoly Service are discussing the possibility of a risk-sharing mechanism in the Russian Federation for public procurement of expensive innovative drugs. If amendments to the law on public procurement are adopted, pharmaceutical companies will only be able to receive payment for drugs if the condition of the patient who takes them improves. The profile commission under the Ministry of Health will have to fix the result of treatment and revise the contracts.